ClearPoint Neuro Reports First Quarter 2024 Results
07 mai 2024 16h05 HE
|
ClearPoint Neuro, Inc.
Q1-2024 Revenue Growth +41%, a Company Record
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
02 mai 2024 16h05 HE
|
ClearPoint Neuro, Inc.
Novel drug delivery research to be presented by ClearPoint Neuro Biologics team at ASGCT 2024 Annual Meeting in Baltimore
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
29 avr. 2024 08h00 HE
|
ClearPoint Neuro, Inc.
FDA Clearance of Prism Bone Anchor Accessory will expand use of the ClearPoint Prism® Neuro Laser Therapy to Operating Room
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
24 avr. 2024 16h05 HE
|
ClearPoint Neuro, Inc.
First 10 operating room procedures with SmartFrame OR successfully completed. Company expects positive impact to revenue in 2024 due to OR expansion.
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
23 avr. 2024 16h05 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro feliciteert partner AviadoBio met de behandeling van de eerste patiënt in klinisch onderzoek ASPIRE-FTD, waarin AVB-101 wordt geëvalueerd voor frontotemporale dementie met GRN-mutaties
17 avr. 2024 15h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californië, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (het “bedrijf”), een internationaal bedrijf dat zich toelegt op hulpmiddelen, cel- en...
ClearPoint Neuro felicita a su socio AviadoBio por el primer paciente tratado en su ensayo clínico ASPIRE-FTD que evalúa AVB-101 en personas con demencia frontotemporal con mutaciones en el gen GRN
17 avr. 2024 15h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, California, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (la «empresa»), una compañía global de dispositivos, células y terapia génica que ofrece navegación...
ClearPoint Neuro si congratula con il proprio partner AviadoBio per il primo paziente trattato nello studio clinico ASPIRE-FTD, che valuta la terapia genica sperimentale AVB-101 per la demenza frontotemporale con mutazioni GRN
17 avr. 2024 15h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, California, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (la “Società”), un’azienda globale di dispositivi, cellule e terapie geniche che offre una...
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird
17 avr. 2024 15h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalifornien, April 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (das „Unternehmen“), ein globales Unternehmen für Geräte, Zellen und Gentherapie, das präzise...
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN
17 avr. 2024 15h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californie, 17 avr. 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq : CLPT) (la « Société »), une société mondiale spécialisée dans les dispositifs, de thérapie cellulaire et...